News & Updates
Filter by Specialty:
Show Multimedia Only

Gemcitabine for IR-NMIBC tied to more recurrence vs BCG
06 Jun 2025
byStephen Padilla
Treatment-naive patients with immediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) who received gemcitabine appear to have greater recurrence risk than those given Bacillus Calmette-Guerin (BCG). Both treatments, however, are effective against disease progression.